RESEARCH ARTICLE

Cost-Effectiveness of a National Initiative to Improve Hand Hygiene Compliance Using the Outcome of Healthcare Associated Staphylococcus aureus Bacteraemia

Nicholas Graves1*, Katie Page1, Elizabeth Martin1, David Brain1, Lisa Hall1, Megan Campbell1, Naomi Fulop2, Nerina Jimmeison3, Katherine White1, David Paterson4, Adrian G. Barnett1

1 Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia, 2 Department of Applied Health Research, University College London, London, United Kingdom, 3 School of Management, Queensland University of Technology, Brisbane, Australia, 4 Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia

* n.graves@qut.edu.au

Abstract

Background
The objective is to estimate the incremental cost-effectiveness of the Australian National Hand Hygiene Initiative implemented between 2009 and 2012 using healthcare associated Staphylococcus aureus bacteraemia as the outcome. Baseline comparators are the eight existing state and territory hand hygiene programmes. The setting is the Australian public healthcare system and 1,294,656 admissions from the 50 largest Australian hospitals are included.

Methods
The design is a cost-effectiveness modelling study using a before and after quasi-experimental design. The primary outcome is cost per life year saved from reduced cases of healthcare associated Staphylococcus aureus bacteraemia, with cost estimated by the annual on-going maintenance costs less the costs saved from fewer infections. Data were harvested from existing sources or were collected prospectively and the time horizon for the model was 12 months, 2011–2012.

Findings
No useable pre-implementation Staphylococcus aureus bacteraemia data were made available from the 11 study hospitals in Victoria or the single hospital in Northern Territory leaving 38 hospitals among six states and territories available for cost-effectiveness analyses. Total annual costs increased by $2,851,475 for a return of 96 years of life giving an incremental cost-effectiveness ratio (ICER) of $29,700 per life year gained. Probabilistic sensitivity analysis revealed a 100% chance the initiative was cost effective in the Australian
Capital Territory and Queensland, with ICERs of $1,030 and $8,988 respectively. There was an 81% chance it was cost effective in New South Wales with an ICER of $33,353, a 26% chance for South Australia with an ICER of $64,729 and a 1% chance for Tasmania and Western Australia. The 12 hospitals in Victoria and the Northern Territory incur annual on-going maintenance costs of $1.51M; no information was available to describe cost savings or health benefits.

Conclusions
The Australian National Hand Hygiene Initiative was cost-effective against an Australian threshold of $42,000 per life year gained. The return on investment varied among the states and territories of Australia.

Introduction
Improved compliance to hand hygiene among healthcare workers will likely contribute to lower rates of healthcare associated infection [1] and improve patient outcomes. Interest in hand hygiene increased with the patient safety movement that emerged in the 1990s [2] and hospitals today are on average safer places than before. The World Health Organisation is leading a global effort to improve hand hygiene compliance with 170 nations signed up to the ‘Clean Care is Safer Care’ campaign. Allegranzi et al. [3] have shown compliance in Costa Rica, Italy, Mali, Pakistan, and Saudi Arabia increased from 51.0% to 67.2%. A version of the WHO campaign was implemented in Germany where more than 700 healthcare institutions participated including 28 university hospitals. There was an absolute increase of 11% in hand hygiene compliance in 62 hospitals [4]. The experience in England and Wales for the period 2004 to 2008 among 187 trust hospitals [5] showed combined procurement of soap and alcohol hand rub tripled, rates fell for MRSA bacteraemia from 1.88 to 0.91 cases per 10,000 bed days, and for C. difficile infection from 16.75 to 9.49 cases per 10,000 bed days, but MSSA bacteraemia rates did not fall. Adjustments were not made for all national concurrent initiatives that would also likely affect MRSA and C. difficile.

Systematic reviews of the evidence for the effectiveness of hand hygiene programmes on hand hygiene compliance have been published [6–10] and two reported pooled results. Schweizer et al. [9] used evidence from three studies to describe a bundle of education, reminders, feedback, administrative support, and access to alcohol-based hand rub to show a pooled odds ratio of 1.82 (95% CI, 1.69–1.97). A further three studies were used to describe a bundle of education, reminders, and feedback that showed a pooled odds ratio of 1.47 (95% confidence interval 1.12–1.94). Luangasanatip et al. [10] did a meta-analysis of two randomised controlled trials and showed the addition of goal setting to the World Health Organization 2005 campaign (WHO-5) was associated with improved compliance (pooled odds ratio 1.35 (95% confidence interval 1.04 to 1.76).

The evidence base for the effectiveness of interventions to improve hand hygiene is growing and programmes are being rolled out globally. Our knowledge of whether these interventions are good value for money is limited. Infection prevention is traditionally underfunded with infection prevention departments seen as cost centres rather than flagship clinical services [11]. Obtaining the largest health returns from scarce infection prevention budgets should be a priority. How improving hand hygiene compliance fits with other infection prevention activities is not well understood [12]. Investing to further improve hand hygiene compliance might
displace other infection prevention efforts such as prospective surveillance, screening and isolating patients, ensuring prophylaxis for surgery is done appropriately, environmental cleaning and antimicrobial stewardship programmes. A balanced portfolio of infection prevention activities that generates the largest health return per dollar invested should be a policy goal [13, 14].

A cost-effectiveness analysis will reveal how improving hygiene compliance impacts on costs and health benefits [13]. These studies report a cost per life year gained and so summarise the value for money of a programme and allow comparison with competing uses of scarce infection control resources [14]. If the health return is low per dollar invested then we might seek other ways to use the infection control budget. If the health return is large then investments in new hand hygiene compliance programmes are justified.

This research describes a national scale initiative funded by the Australian Commission on Safety and Quality in Health Care implemented between 2009 and 2012 in all states and territories of Australia. It was managed by Hand Hygiene Australia [15] and there were three stated goals. To achieve widespread adoption of the World Health Organisation’s ‘five moments’ programme [16]. To apply a single training programme that allows healthcare workers responsible for hand hygiene to teach and measure compliance in a similar way. To promote accurate measurement of new hospital-associated *Staphylococcus aureus* bacteraemia infections using a standard definition, suggested as a valid and sensitive outcome measure for hand hygiene [17, 18]. The national programme was designed to be simple to use and allow outcomes to be compared across Australia and internationally.

The national initiative augmented existing local efforts to improve hand hygiene compliance among the eight states and territories of Australia. In Queensland (QLD) there was an existing programme that promoted 11 tasks of hand hygiene [19], funded by the state health department and implemented in all QLD hospitals by the Centre for Healthcare Related Infection Surveillance and Prevention. Some data were reported that showed high compliance but there was little education for auditors and relatively few numbers of observations were recorded. In South Australia (SA) and Western Australia (WA) there were campaigns within single hospitals but no state wide implementation other than the health department providing support material such as posters. In Tasmania (TAS), Australian Capital Territory (ACT) and Northern Territory (NT) there were no hospital level or state level campaigns. In New South Wales (NSW) there was a state funded programme starting in 2006 [20]. It included education, measurement of alcohol based hand rub usage and auditing of hand hygiene behaviour with feedback to staff. In Victoria (VIC) the state health service funded a pilot programme at the Austin Hospital for six sites [21] that was subsequently expanded to a state wide programme [22]. Grayson et al [22] reported a statistically significant reduction in MRSA clinical isolates per 100 patient days of −0.018 per month (95% CI −0.024 to −0.011, p-value < 0.001). This analysis incorrectly assumed rates were flat prior to implementation. A re-analysis of the same data that allowed an appropriate linear decrease in rates before the intervention showed effectiveness is reduced to −0.007 and is not statistically significant (95% CI −0.019 to 0.006, p-value = 0.31) [23]. Playford at el. [24] found counterintuitively that hand hygiene compliance and healthcare associated *Staphylococcus aureus* bacteraemia were positively correlated, and their data came from 21 large Australian metropolitan public hospitals. They caution against using healthcare associated *Staphylococcus aureus* bacteraemia as a sole indicator of the impact of HH compliance citing other important causal factors in the relationship.

The objective for this paper is to report the incremental change to costs and health outcomes relating to healthcare associated *Staphylococcus aureus* bacteraemia infections from a decision to adopt the National Hand Hygiene Initiative implemented between 2009 and 2012.
Methods

The design was a cost-effectiveness modelling study to predict the change to the number of cases of healthcare associated *Staphylococcus aureus* bacteraemia, change to years of life lost among inpatient admissions, and change to total health services costs defined by the annual on-going maintenance costs less the cost savings from fewer cases of *Staphylococcus aureus* bacteraemia infection. Data have been collected for the National Hand Hygiene Initiative on compliance rates for each of the five hand hygiene moments since 2009. The number of moments recorded has increased from 127,125 in November 2009 to 461,082 in March 2013 and compliance rose from 61.8% to 76.9% during this time [25]. We chose not to use this measure as an outcome for this study because: healthcare workers might only improve their hand hygiene while they are observed by auditors [26]; many of the data were missing; large discrepancies between the performance of nursing and medical staff will bias the reported averages [27]; and, most important is that reliable and complete outcomes were available for *Staphylococcus aureus* bacteraemia in the time periods before and after implementation of the National Hand Hygiene Initiative.

*Staphylococcus aureus* bacteraemia is the only infection outcome included for this study and the definition has been published [28], see Appendix A in S1 File. *Staphylococcus aureus* bacteraemia is the only healthcare associated infection with a nationally agreed definition among the eight jurisdictions of Australia [29]. Cases of *Staphylococcus aureus* bacteraemia have large costs arising from extra days stay in hospital required to treat symptoms [30] and so their reduction will show the largest possible cost savings. Acquisition also increases mortality risk substantially [30, 31] and quantifying reduction is an opportunity to show the health benefits of infection control in ‘years of life gained’, which is a suitable outcome measure for cost-effectiveness research [32]. The steering committee formed to oversee this cost-effectiveness evaluation made up of representatives of Hand Hygiene Australia, The Australian Commission on Safety and Quality in Health Care, and all the state and territory health departments strongly advised the research team not to include data on other infection outcomes, due to inconsistency in how they had been measured among the 8 state and territory health services. This is confirmed by recent evidence that shows great variability in surveillance practices among the eight states and territories [33].

Cost and effectiveness outcomes were estimated separately for each state and territory of Australia, using the comparator of the pre-existing and locally organised hand hygiene initiatives. The cost per life year gained was used to judge the cost-effectiveness of the national initiative and arose from dividing change to total cost by the change to life years gained. Total cost was the ongoing implementation costs less the cost savings from fewer cases of *Staphylococcus aureus* bacteraemia. The perspective adopted was acute services funded by the state and territory health department, because a decision to continue investing in hand hygiene programmes would be made at this level rather than nationally. Future costs and health benefits were discounted at 3% [34]. Model outcomes were evaluated for a 12-month period after the implementation of the National Hand Hygiene Initiative, 2011–2012. How information was structured to predict incremental cost-effectiveness is shown in Fig 1.

Setting and Patients

Data were collected from the 50 largest acute public hospitals in Australia representative of the eight states and territories, Appendix B in S1 File. The sample was the five largest public hospitals by number of acute beds in NSW, VIC, QLD, WA and SA, the three largest public hospitals in TAS, and the single main public hospital in NT and the ACT; the next largest 20 public hospitals Australia-wide were then selected. These hospitals provide 42% of the public acute beds
in Australia and suggest a sample that can be generalised from. There were 1,294,656 admissions to 24,482 beds included in the cost-effectiveness model for the 12-month period in 2011–2012, Table 1. No useable pre-intervention Staphylococcus aureus bacteraemia data were made available from 11 hospitals in VIC or the single hospital in NT. No private hospitals were included in the study.

Evaluation of the impact of National Hand Hygiene Initiative on Staphylococcus aureus bacteraemia

Reductions in risk of Staphylococcus aureus bacteraemia from the introduction of the national initiative were estimated using 2,304 monthly infection rates across 38 hospitals in six states and territories. A brief summary is provided and a complete description of the statistical method and results are available [35]. There was variability in the start date among sites, Appendix C in S1 File. The average number of months for which data were available before the intervention was 29 per hospital, with an average post-intervention time of 32 months. A before and after quasi-experimental design [36] was used to compare rates of Staphylococcus aureus bacteraemia in pre and post-intervention time periods. Analyses were conducted separately for each state and territory because the intervention was implemented at slightly different times, there were important differences in average infection rates, pre-existing hand hygiene campaigns varied and there were different infection prevention policies. We controlled for seasonal patterns in rates using a categorical variable for month and we used a random intercept in each hospital to control for differences in the average infection rates between hospitals. We were not interested in differences between hospitals and
estimated the within-hospital change due to the intervention, and the average within-hospital change per state.

Costing Information

The costs of the initiative were incurred by Hand Hygiene Australia at a national level and by the co-ordinating patient safety group in each state and territory. The estimates reflect the annual on-going maintenance costs and establishment and research costs have been excluded. Prospective surveys were used to estimate the costs of extra alcohol based hand rub and the time costs incurred by the infection control practitioners and other staff who worked in each of the 50 study hospitals to support the initiative. All costing methods are summarised in Appendix D in S1 File, a detailed description of the methods are available as are a complete set of cost results [37, 38]. All cost parameters used are summarised in Appendix E in S1 File.

Cost savings arose from reduced length of stay in ward and ICU beds because cases of *Staphylococcus aureus* bacteraemia were prevented. Estimates of the extra days saved per case of *Staphylococcus aureus* bacteraemia came from a survival model that appropriately accounts for the timing of infection during the admission [39, 40] and the results of this work are published [41]. The parameter values used are shown in Table 2. The dollar value assigned for a ward bed day was obtained from a summary of 2011–12 expenditure and activity for Australian Public Hospitals [42]. The value of an ICU bed day was obtained from a costing study of ICU admissions to a public hospital in Australia [43] and adjusted to 2011 prices based on a rate of health spending inflation [44], Table 2.

Table 1. Information used to estimate the number of cases of *Staphylococcus aureus* bacteraemia (SAB) prevented by the National Hand Hygiene Initiative.

| State/Territory | Hospitals | Beds | Admissions | Mean | St. Dev. | Mean | 95% CI | Mean | St. Dev. |
|-----------------|-----------|------|------------|------|----------|------|--------|------|----------|
| QLD             | 9         | 5,366| 246,699    | 1.48 | 1.08     | 17%  | 6 to 27%| 0.83 | 0.10     |
| ACT             | 1         | 619  | 31,841     | 2.91 | n/a      | 28%  | 6 to 45%| 0.72 | 0.24     |
| NSW             | 15        | 7,739| 404,869    | 2.60 | 1.38     | 11%  | 7 to 16%| 0.90 | 0.08     |
| SA              | 5         | 2,065| 122,435    | 2.08 | 2.05     | 8%   | 1 to 15%| 0.92 | 0.13     |
| TAS             | 3         | 1,007| 41,850     | 0.90 | 0.68     | 0%   | -52 to 34%| 1.00 | 0.21     |
| WA              | 5         | 2,167| 122,025    | 1.96 | 1.62     | 0%   | -22 to 18%| 1.00 | 0.17     |
| VIC             | 11        | 5,184| 305,270    | No data | No data | No data | No data | No data | No data |
| NT              | 1         | 335  | 19,667     | No data | No data | No data | No data | No data | n/a     |
| Total           | 50        | 24,482| 1,294,656  |      |          |      |        |      |          |

QLD = Queensland, ACT = Australian Capital Territory, NSW = New South Wales, SA = South Australia, TAS = Tasmania, WA = Western Australia, VIC = Victoria, NT = Northern Territory.

* Per 10,000 bed days.
† 12 months post intervention.

For the complete set of cost results and the detailed description of the costing methods, see the S1 File.
Risks of death from *Staphylococcus aureus* bacteraemia

The extra risk of death from *Staphylococcus aureus* bacteraemia was estimated using the same survival model used to predict extra length of stay [41], and the findings are the number of deaths averted from fewer cases of *Staphylococcus aureus* bacteraemia per hospital. The analysis revealed 16.7% deaths among cases and 5.9% deaths among controls and the log of the hazard ratio was 1.27 (s.e. = 0.13). A normally distributed log relative risk was used for the cost-effectiveness modelling and the exponent used to update model results. The extra years of life gained from a death averted due to *Staphylococcus aureus* bacteraemia was the difference between the mean age at death among those who died in the sample, and life expectancy based on Australian life tables [45]. All relevant values used for the modelling are shown in Table 2.

Model Estimation

Prior statistical distributions were fitted to each of the parameters of the model at the level of the hospital to capture uncertainty in the information used. Normal distributions were suitable for most parameters. For the cost parameters gamma distributions were appropriate to ensure costs were positive. Uniform distributions were used where no information on the shape of the distribution was available and only high and low estimates were available. The model was simulated for 5,000 random draws from all distributions, giving 5,000 estimated results for all outcome measures. The highest and lowest 2.5% for each outcome measure were used to show 95% uncertainty intervals. The probability the National Hand Hygiene Initiative is cost-effective is the proportion of 5,000 resamples with a cost per life year saved below an Australian threshold value of $42,000 per life year saved. This figure was chosen based on analysis of decisions made by the Australian government to fund new drugs from the public purse [46]. This approach to generating cost-effectiveness information is called probabilistic sensitivity analysis and has been shown to have wide applicability for health services decision-making [47–49]. A worked example and discussion of how this method applies to the economic evaluation of hand hygiene initiatives has been published [50]. The data used for the model are available, see S1 Data.

Ethics Statement

This research was undertaken with approved ethical clearance by the University and the Hospitals’ Human Research Ethics Committees. The reference numbers for the ethical clearances

| Table 2. Values used to estimate cost savings and years of life gained per *Staphylococcus aureus* bacteraemia avoided. |
|---------------------------------------------------------------|
| Extra Days saved per SAB avoided (mean, se)                  |
| Ward bed, patient died                                       |
| Ward bed, patient discharged                                 |
| ICU bed, patient died                                        |
| ICU bed, patient discharged                                  |
| Dollar value used, Minimum to Maximum                        |
| Ward bed day (min to max)                                    |
| ICU bed day (min to max)                                     |
| Mean age at death (s.e.)                                     |
| Life expectancy                                              |
| Years life lost (discounted at 3%)                           |

| Ward bed, patient died | 1.00 (2.60) |
| Ward bed, patient discharged | 11.40 (2.22) |
| ICU bed, patient died | 1.60 (0.69) |
| ICU bed, patient discharged | 1.00 (0.56) |
| Ward bed day (min to max) | $919 to $1,252 |
| ICU bed day (min to max) | $3503 to $4,282 |
| Mean age at death (s.e.) | 62.00 (0.219) |
| Life expectancy | 69.70 |
| Years life lost (discounted at 3%) | 7.70 (6.78) |

doi:10.1371/journal.pone.0148190.t002
are: Queensland Health. HREC/10/QPAH/180 (hospitals) and QUT HREC 1000001240 (University). For New South Wales all 15 sites were covered by this single HRECs approval. Sydney Local Health District (Concord) HREC (Ref: LNR/12/CRGH/44CH62/6/2012-038). For Victoria there were 11 sites in the study covered by 10 different HRECs: Box Hill Hospital: Eastern Health HREC (Ref: LR89/1112); Frankston Hospital: Peninsula Health Quality and Clinical Governance (Ref: HREC/12/PH/39); Geelong Hospital; Monash Medical Centre and Dandenong Hospital: Southern Health Research Directorate—Quality Assurance (Ref: 12114Q); Western Hospital: Western Health Low Risk Human Research Ethics Panel, Office for Research (Ref: QA 2012/77); The Alfred Hospital: The Alfred Ethics Committee (Ref: 217/12); St Vincent’s: Research Governance Office (Ref: LRR071/12); The Austin Hospital: Austin Health HREC, Research Ethics Unit (Ref: H2012/04672); Royal Melbourne: Melbourne Health HREC (Ref: QA 201090); The Northern Hospital: The Northern Hospital HREC Office (Ref: LR 13/12). For Western Australia there were 5 sites in the study covered by 3 different HRECs: Sir Charles Gairdner Hospital, King Edward Memorial Hospital and Princess Margaret Hospital: Sir Charles Gairdner HREC (Ref: 2011-108); Fremantle Hospital: Southern Metropolitan Area Health Service HREC (Ref: S/11/289); Royal Perth Hospital: Royal Perth Ethics Committee (Ref: RA-11/024). For Northern Territory there was only 1 site in the study from Northern Territory, Human Research Ethics Committee of Northern Territory Department of Health and Menzies School of Health Research (Ref: HREC-11-1543). For South Australia there were 5 sites in the study from South Australia, covered by 3 different HRECs: Lyell McEwin and The Queen Elizabeth Hospital were covered by SA Human Health Research Ethics Committee (Ref: 20111108); Royal Adelaide Hospital was covered by Royal Adelaide Hospital Research Ethics Committee (Ref: 110712); Flinders Medical Centre and Repatriation General Hospital were covered by Southern Adelaide Health Service Clinical Research Ethics Committee (Ref: EC00188). For Queensland there were 9 sites in the study from Queensland, covered by 2 different HRECs: RBWH, Townsville, Gold Coast, Logan, Prince Charles, Princess Alexandra, Nambour and Cairns Base were all covered by the Metro South Health Service District HREC (Ref: HREC/10/QPAH/180); Ipswich hospital was covered by reference: AU/1/3BO7013/HREC/10/QWMS/40. For Tasmania there were 3 sites in the study covered by 1 HREC, Office of Research Services, University of Tasmania, Human Research Ethics Committee (Ref: H11999). For Australian Capital Territory there was 1 site in the study covered by ACT Health HREC (Ref: ETHLR.12.050). Written informed consent was given by participants who answered all surveys used for the study. All clinical/patient records were anonymous and de-identified.

Results

The largest effect from the initiative was found in ACT with a 28% immediate reduction of *Staphylococcus aureus* bacteraemia infection risk that was sustained for 12 months. QLD also showed an immediate reduction of 17% of *Staphylococcus aureus* bacteraemia risk that was sustained for 12 months. There were linear reductions in NSW and SA that resulted is risks being lower at 12 months post intervention by 11% and 8% respectively. There were no discernible mean changes to infection risks in TAS and WA after the adoption of the initiative, Table 1.

For the six states and territories that provided complete data on *Staphylococcus aureus* bacteraemia total annual costs arising from the National Hand Hygiene Initiative were $2,851,475 for a return of 96 years of life, an incremental cost-effectiveness ratio of $29,700 per life year gained. This is below the threshold for cost-effectiveness of $42,000 per life year gained used for this study [46]. As the decision to fund hand hygiene programmes lies with each state and territory we report the rest of the results at that level, Table 3 and Fig 2. The largest increases to
The number of bed days saved is reported in Appendix F in S1 File.

There were gains to health benefits in four states, but negligible gains in TAS or WA where the initiative had no virtually no impact on *Staphylococcus aureus* bacteraemia outcomes. The

**Table 3. Change to outcomes from adoption of National Hand Hygiene Initiative & Probability an Adoption Decision was Cost-Effective.**

| Cases of *Staphylococcus aureus* bacteraemia prevented | Total Costs | Health Benefits in Life Years Gained | Cost per life year gained | Probability cost-effective |
|--------------------------------------------------------|------------|-------------------------------------|--------------------------|---------------------------|
| QLD 27.48 (23.75–31.22)                               | $355,344 ($166,561 - $526,681) | 39.53 (28.74–52.63)           | $8,988                   | 100%                      |
| ACT 9.74 (5.08–14.43)                                  | $14,439 (-$155,769 - $151,012) | 14.01 (6.85–22.50)            | $1,030                   | 100%                      |
| NSW 24.73 (18.41–31.22)                               | $1,187,067 ($954,645 - $1,398,475) | 35.59 (23.86–50.05)            | $33,353                  | 81%                       |
| SA 4.75 (-1.03–10.55)                                  | $442,807 ($273,290 - $605,656) | 6.84 (-1.48–15.64)            | $64,729                  | 26%                       |
| TAS 0.01 (-2.47–2.52)                                  | $256,247 ($170,356 - $343,044) | 0.02 (-3.63–3.68)             | $10,371,874              | 1%                        |
| WA 0.01 (-6.00–6.10)                                   | $595,471 ($441,030 - $753,395) | 0.01 (-8.81–8.76)             | $63,332,051              | 1%                        |

QLD = Queensland, ACT = Australian Capital Territory, NSW = New South Wales, SA = South Australia, TAS = Tasmania, WA = Western Australia

* In ACT there is a 41% probability it was cost saving

![Fig 2. Cost increases and cost savings by state and territory for the National Hand Hygiene Initiative.](#)

doi:10.1371/journal.pone.0148190.g002
initiative was cost-effective when judged against the threshold value of $42,000 per life year gained in QLD, ACT and NSW, but was not cost-effective in SA, TAS or WA, meaning that remaining with the local initiative was a better decision for the latter three states. The probabilistic sensitivity analysis showed a high probability the decision to adopt the national programme was cost effective in QLD, ACT and NSW, but a probability lower than 50% was found for the other three states and territories. This is shown explicitly by the data included in Appendix G in S1 File. The generalizability of the model results is supported by the fact that 24,482 bed-days supplied by the study hospitals accounted for 42% of all public beds in Australia, and that the number of *Staphylococcus aureus* bacteraemia included in the model for the 12 months prior to the initiative was 1,617, which represents 93% of all the cases of reported for every Australian hospital in 2010–11 [51].

**Other infection outcomes not included in cost-effectiveness model**

Some data were available for other infection outcomes. Rates of all bloodstream infection (BSI), central line related blood stream infection (CLABSI), methicillin resistant *Staphylococcus aureus* (MRSA), methicillin sensitive *Staphylococcus aureus* (MSSA) and surgical site infection (SSI) were obtained from all the states and territories in the study and analysed using an appropriate statistical method [23]. Not all jurisdictions collected all these outcomes and only a patchwork was available. These outcomes were not included in the cost-effectiveness model because the definitions and data collection approaches used to obtain these data are not consistently applied across the country [29] and these infection outcomes make subsets of each other. For example ‘all blood stream infections’ will include *Staphylococcus aureus* bacteraemia and CLABSI; and SSI infections will contain some MRSA and MSSA cases. The results for these other infection outcomes are reproduced from the original publication [23] in Fig 3. The National Hand Hygiene Initiative was associated with a statistically significant reduction in infection rates in 11 out of 23 state and infection combinations studied. There was no change in infection rates for 9 combinations, and there was an increase in three infection rates in South Australia.

**Discussion**

This is the first cost-effectiveness evaluation of a National Hand Hygiene Initiative and shows that overall the programme was cost effective with a cost per life year gained of $29,700. It was strongly cost-effective in QLD and ACT, somewhat cost-effective in NSW but exceeded the threshold value of $42,000 per life year gained in SA, TAS and WA. The health returns and cost savings from the investment made in VIC and NT [52] are unknown as useable pre-intervention *Staphylococcus aureus* bacteraemia data were not available. This result corresponds with a recent and high quality evaluation of a decade of investment in infection prevention that showed an incremental cost-effectiveness ratio of $14,250 per life year gained ($19,479 AUD) for interventions to reduce risk of ventilator associated pneumonia and $23,277 per life year gained ($31,835 AUD) for interventions to reduce risk of central line associated blood stream infections [53].

The large variability in the cost-effectiveness results among the states and territories likely has multiple factors. Hand hygiene appears cost effective where pre intervention rates were not declining, Queensland and the ACT. Other settings such as Tasmania were on the path toward improvements regardless of the national programme and the relatively high additional cost of the national programme were not sufficiently rewarded with health benefits from fewer cases of *Staphylococcus aureus* bacteraemia. Recent research shows that hand-hygiene was only effective in time-periods where infection rates were above a critical threshold and the highest
impacts where in areas of higher baseline infection rates [54]. Policy makers might conclude that the intensity of hand-hygiene campaigns be adapted to variability in local conditions. Strain dynamics might also contribute to variability in cost-effectiveness. Lawes et al. [55] showed the impact of infection prevention is strain-specific. In particular when hospital epidemiology is dominated by community associated strains, hospital based interventions have lower impact.

An important caveat is the process used to generate the effectiveness information included in the cost-effectiveness modelling [35]. As this was a national initiative there were no hospitals to act as controls and the findings are vulnerable to other changes to infection control policy. The potential for confounding is somewhat mitigated because the initiative was started at different times among the 38 study sites. This will reduce the overall correlation between the intervention and other changes. Better quality evidence would have emerged from a prospective study using a cluster randomised controlled trial or a stepped wedge design [56] as the initiative was rolled out. Yet national public health priorities often over-ride the need to do prospective evaluation with a stronger design. An opportunity to use a better design would have helped disentangle the complex effects of the likely multiple modifiable ecological factors such as antibiotic stewardship, isolation, decolonisation and improvement to hand-hygiene [57]. As with many of these projects the request to evaluate the cost-effectiveness of the initiative came after the programme had commenced making retrospective evaluation the only
option. Policy makers in the future might evaluate the cost-effectiveness of a new health programme prior to national implementation.

That only *Staphylococcus aureus* bacteraemia outcomes were included is also important and means this could be a conservative estimate of the health benefits of improving hand hygiene compliance. Lawes et al [54] have shown reduced community MRSA from improving infection prevention in acute hospitals. If other infections were reduced then further cost savings and health benefits would have accrued for no extra implementation cost. The effect of this would be larger cost savings, lower total cost and higher health benefits. The patchy evidence assembled for other infection outcomes does not show significant reductions in all of the infection combinations studied. Indeed there were increases in rates of all BSI, MRSA and SSI in South Australia. This is plausible with infection control professionals in the study hospitals reporting that many of their existing tasks were displaced by the extra demands from implementing the National Hand Hygiene Initiative. Evidence would suggest that hand hygiene improvements are less effective at interrupting endogenous transmission, more likely for MSSA, than exogenous transmission, which in the hospital settings is more likely to be associated with MRSA. The English ‘clean your hands’ evaluation [5] showed no association between hand hygiene consumables use and methicillin sensitive *Staphylococcus aureus* bacteraemia. The data we had available for all MRSA, shown in Fig 3, do not however show dramatic reductions.

Only including ward and ICU bed day costs might understate the true cost savings from an avoided case of *Staphylococcus aureus* bacteraemia. It is possible that other savings occurred in the primary care sector such as interactions with community nurses, but we judge these to be a small proportion of the total costs of *Staphylococcus aureus* bacteraemia. Another related issue is that accounting costs used to value the bed days saved, $919 to $1,252 for a ward bed and $3503 to $4,282 for an ICU bed. A recent contingent valuation study elicited the economic value of a hospital bed day from a sample of 11 European hospitals [58] and found values of €72 per ward bed day and €190 per ICU bed day, much lower than the accounting costs. The impact of using lower values per bed day saved would be to dramatically reduce the cost savings and so increase the total costs of the initiative, worsening the cost-effectiveness ratios. The ‘economic’ rather than the ‘accounting’ value is the correct one to use for informing decisions about how scarce resources are used [13, 59]. Life years gained rather than quality adjusted life years gained was the measure of health benefit. Including a preference based utility decrement for the time patients spent with symptoms from *Staphylococcus aureus* bacteraemia will make a very small difference to health benefits, because the mortality benefit was for multiple years and the time in a *Staphylococcus aureus* bacteraemia state was less than two weeks. Whether the programme has matured, impacting on cost-effectiveness for time periods after 2011 to 2012 is not known, and would require new data collection.

The pressing question for policy makers is whether cheaper health returns could have been achieved by allocating scarce infection prevention budgets to programmes that were displaced by the National Hand Hygiene Initiative. This is an empirical question and requires models of the cost-effectiveness of other programmes. If the screening and isolation of in-patients, or the expansion of environmental cleaning programmes or establishing of antimicrobial stewardship programmes generated health benefits at a lower cost than improving hand hygiene, then resources should be re-allocated appropriately. The impact of this would be to increase health benefits from scarce infection prevention resources. A balanced portfolio of infection prevention activities that generates the largest health return per dollar invested is a sensible policy goal, and cost-effectiveness data are important for achieving it.
Supporting Information

S1 File. Appendix A. The source for this definition is the Australian Commission on Safety and Quality in Health Care. Appendix B. The 50 study hospitals selected for cost-effectiveness evaluation. Appendix C. Time periods for which Staphylococcus aureus bacteraemia data were available for each of the study hospitals (n = 38). Circles denote the start date of the National Hand Hygiene Initiative. Appendix D Summary of Costing Methods. Appendix E. Costing information used for modelling. Appendix F. Number of bed days saved from adoption of National Hand Hygiene Initiative. Appendix G. Uncertainty for cost-effectiveness outcomes, 1000 simulations shown for each state and territory. Results of probabilistic sensitivity analysis. (DOCX)

S1 Data. Data used for the cost-effectiveness modelling. (XLSM)

Acknowledgments

The Centre for Healthcare Related Infection Surveillance and Prevention, Communicable Diseases Branch, Queensland Health, supports the salaries of NG & DP. We are grateful to all the infection control practitioners who took their time to answer the costing survey and provide other information about the implementation of the National Hand Hygiene Initiative. All authors have no relationships with companies that might have an interest in the submitted work; their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and they have no non-financial interests that may be relevant to the submitted work.

Notes

Contributors: All authors conceived and drafted the study, and analysed and interpreted the data. NG drafted the manuscript, and all authors approved the final draft of the manuscript. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding: Financial Support. National Health and Medical Research Council Partnership Grant (number 553081) with financial and in-kind support from: Australian Commission on Safety and Quality in Health Care, Hand Hygiene Australia, and jurisdictional health departments. Representatives of the Australian Commission on Safety and Quality in Health Care attended research governance meetings to provide feedback on the progress of the project, but the design and conduct is the sole responsibility of the Investigators awarded the grant. The funders had no veto on study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Conceived and designed the experiments: NG KP EM DB LH MC NF NJ KW DP AB. Performed the experiments: NG KP EM DB LH MC NF NJ KW DP AB. Analyzed the data: NG DB AB. Contributed reagents/materials/analysis tools: NG KP EM DB LH MC NF NJ KW DP AB. Wrote the paper: NG KP EM DB LH MC NF NJ KW DP AB.
References

1. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, et al. Health care-associated invasive MRSA infections, 2005–2006. JAMA. 2010; 304(6):641–8. Epub 2010/08/12. doi: 10.1001/jama.2010.1115 PMID: 20699455.

2. Kohn LT CJ, Donaldson MS, To Err Is Human: Building a Safer Health System. National Academy Press. Washington, DC.: Institute of Medicine of the National Academy of Sciences; 1999.

3. Allegranzi B, Gayet-Ageron A Fau — Damani N, Damani N Fau — Bengaly L, Bengaly L Fau — McLaw M-L, McLaw M Fau — Moro M-L, Moro M Fau — Memish Z, et al. Global implementation of WHO’s multimodal strategy for improvement of hand hygiene: a quasi-experimental study. (1474–4457 (Electronic)).

4. Reichardt C, Koniger D, Bunte-Schonberger K, van der Linden P, Monch N, Schwab F, et al. Three years of national hand hygiene campaign in Germany: what are the key conclusions for clinical practice? J Hosp Infect. 2013; 83 Suppl 1:S11–6. Epub 2013/03/15. doi: 10.1016/j.jhin.2013.02.004 PMID: 23453170.

5. Stone SP, Fuller C Fau — Savage J, Savage J Fau — Cookson B, Cookson B Fau — Hayward A, Hayward A Fau — Cooper B, Cooper B Fau — Duckworth G, et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. (1756–1833 (Electronic)). D—NLM: PMC3343183 EDAT- 2012/05/05 06:00 MHDA- 2012/06/27 06:00 CRDT- 2012/05/05 06:00 PST—epublish.

6. Naikoba S, Hayward A. The effectiveness of interventions aimed at increasing handwashing in health-care workers—a systematic review. 2001;(0195–6701 (Print)).

7. Gould DJ, Moralejo D, Drey N, Chudleigh JH. Interventions to improve hand hygiene compliance in hospital care workers. Cochrane Database of Systematic Reviews 2010;Issue 9. Art. No.: CD005186. doi: 10.1002/14651858.CD005186.pub3

8. Huis A, van Achterberg T Fau — de Bruin M, de Bruin M Fau — Grol R, Grol R Fau — Schoonhoven L, Schoonhoven L Fau — Hulscher M, Hulscher M Fau — A systematic review of hand hygiene improvement strategies: a behavioural approach. (1748–5908 (Electronic)). D—NLM: PMC3517511 EDAT- 2012/09/18 06:00 MHDA- 2013/04/23 06:00 CRDT- 2012/09/18 06:00 PHST- 2012/01/11 [accepted] PHST- 2012/09/23 [accepted] PHST- 2012/09/14 [aheadofprint] AID- 1748-5908-7-92 [pii] AID- 10.1186- 1748-5908-7-92 [doi] PST—epublish.

9. Schweizer ML, Reisinger HS Fau — Ohl M, Ohl M Fau — Formanek MB, Formanek MB Fau — Blevins A, Blevins A Fau — Ward MA, Ward MA Fau — Perencevich EN, et al. Searching for an optimal hand hygiene bundle: a meta-analysis. (1537–6591 (Electronic)).

10. Luangasanatip N, Hongsuwan M, Limmathurotsakul D, Lubell Y, Lee AS, Harbarth S, et al. Comparative efficacy of interventions to promote hand hygiene in hospital: systematic review and network meta-analysis. BMJ. 2015; 351:h3728. Epub 2015/07/30. doi: 10.1136/bmj.h3728 PMID: 26220070; PubMed Central PMCID: PMCPMC4517539.

11. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN, Cosgrove SE. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol. 2007; 28(10):1121–33. Epub 2007/10/16. doi: 10.1086/521852 PMID: 1793084.

12. McLaw M, Pantle AC, Fitzpatrick KR, Hughes CF. More than hand hygiene is needed to affect methicillin-resistant Staphylococcus aureus clinical indicator rates: clean hands save lives, part IV. Med J Aust. 2009; 191(8 Suppl):S26–31. Epub 2009/10/20. PMID: 19835528.

13. Graves N. Economics and preventing hospital-acquired infection. Emerg Infect Dis. 2004; 10(4):561–6. PMID: ISI:000220578600001.

14. Graves N, Halton K, Lairson D. Economics and preventing hospital-acquired infection: broadening the perspective. Infect Control Hosp Epidemiol. 2007; 28(2):178–84. Epub 2007/02/01. ICHE2005206 [pii] doi: 10.1086/510787 PMID: 17265399.

15. Grayson ML, Russo PL. The national hand hygiene initiative. Med J Aust. 2009; 191(8):420–1. Epub 2009/10/20. PMID: 19835531.

16. Sax H, Allegranzi B, Uckay I, Larson E, Boyle J, Pittet D. ‘My five moments for hand hygiene’: a user-centred design approach to understand, train, monitor and report hand hygiene. J Hosp Infect. 2007; 67(1):9–21. Epub 2007/08/28. doi: 10.1016/j.jhin.2007.06.004 PMID: 17719685.

17. Collignon P, Wilkinson LJ, Gilbert GL, Grayson ML, Whitby RM. Health care-associated Staphylococcus aureus bloodstream infections: a clinical quality indicator for all hospitals. Med J Aust. 2006; 184(8):404–6. Epub 2006/04/19. PMID: 16618240.

18. Collignon PJ Fau — Cruickshank M, Cruickshank M. Staphylococcus aureus bacteraemias: time to act. (0025–729X (Print)).
19. Centre for Healthcare Related Infection Surveillance and Prevention. http://www.health.qld.gov.au/qhpolicy/docs/gdlt/qh-gdl-321-1-1.pdf. 2013.
20. Pantle AC, Fitzpatrick KR, McLaws ML, Hughes CF. A statewide approach to systematising hand hygiene behaviour in hospitals: clean hands save lives, part I. Med J Aust. 2009; 189(8 Suppl):S8–S12. Epub 2009/10/20. PMID: 19835530.
21. Johnson PD, Martin R, Burrell LJ, Grabsch EA, Kirsch SW, O’Keefe J, et al. Efficacy of an alcohol/chlorhexidine hand hygiene program in a hospital with high rates of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection. Med J Aust 2005; 183(10):509–14. PMID: 16296963
22. Grayson ML, Martin R, Johnson PD, Jodoin ME, McAllan C, et al. Signiﬁcant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multi-site, hand hygiene culture-change program and subsequent successful statewide roll-out. Med J Aust. 2008; 188(11):633–40. PMID: 18513171
23. Barnett A, Page K, Campbell M, Brain D, Martin E, Winters S, et al. Changes in healthcare associated infections after the introduction of the National Hand Hygiene Initiative. Healthcare Infection. 2014; 19:128–34.
24. Playford EG, McDougall D, McLaws ML. Problematic linkage of publicly disclosed hand hygiene compliance and health care-associated Staphylococcus aureus bacteraemia rates. Med J Aust. 2012; 197(1):29–30. Epub 2012/07/06. PMID: 22762227.
25. Hand Hygiene Australia. National Data, available at http://www.hha.org.au/LatestNationalData.aspx. 2014.
26. Srigley JA, Furness CD, Baker GR, Gardam M. Quantification of the Hawthorne effect in hand hygiene compliance monitoring using an electronic monitoring system: a retrospective cohort study. BMJ Qual Saf 2014; 23(12):974–80. D—NLM: PMC4251174 OT0—NOTNLM. doi: 10.1136/bmjqs-2014-003080 PMID: 25002555
27. Azim S, McLaws ML. Doctor, do you have a moment? National Hand Hygiene Initiative compliance in Australian hospitals. Med J Aust. 2014; 200(9):534–7. Epub 2014/05/20. PMID: 24835717.
28. ACSQHC. Surveillance of Healthcare Associated Infections: Staphylococcus aureus bacteraemia & Clostridium difﬁcile infection. Version 4.0. Available here: http://www.safetyandquality.gov.au/wp-content/uploads/2012/03/Data-Set-Specification-Surveillance-of-Healthcare-Associated-Infections-SAB-and CDI-V-4.pdf. 2012.
29. Australian Commission on Safety and Quality in Health Care. Implementation Guide for Surveillance of Staphylococcus aureus Bacteraemia. Available here http://www.safetyandquality.gov.au/wp-content/uploads/2012/02/SAQ019_Implementation_guide_SAB_v10.pdf. Sydney, Australia 2013.
30. Pittet D, Tarara D, Wenzel RP. Nosocomial Bloodstream Infection in critically Ill Patients. Excess length of stay, extra costs and attributable mortality. J Am Med Assoc. 1994; 271:1598–601.
31. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012; 25(2):362–86. Epub 2012/04/12. doi: 10.1128/cmr.05022-11 PMID: 22491776; PubMed Central PMCID: PMCPmc3346297.
32. Weinstein MC. Foundation of cost-effectiveness analysis for health and medical practices. New Engl J Med. 1981; 296(31):716–21.
33. Russo PL, Cheng AC, Richards M, Graves N, Hall L. Variation in health care-associated infection surveillance practices in Australia. American Journal of Infection Control. doi: 10.1016/j.jhin.2015.02.029
34. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013 available at, http://www.nice.org.uk/article/prmg9/chapter/the-reference-case#/discounting 2013.
35. Barnett AG, Page K, Campbell M, Brain D, Martin E, Winters S, et al. Changes in healthcare-associated Staphylococcus aureus bloodstream infections after the introduction of a national hand hygiene initiative. Infect Control Hosp Epidemiol. 2014; 35(8):1029–40. PMID: 25092619.
36. Fendler J, Gaedeke P, Grundmann H, Barwolff S, Geefers C, Behnke M, et al. Use of multistate models to assess prolongation of intensive care unit stay due to nosocomial infection. Infect Control Hosp Epidemiol. 2006; 27(5):493–9. PMID: 16671031
40. Barnett AG, Beyersmann J, Allignol A, Rosenthal VD, Graves N, Wolkewitz M. The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value Health. 2011; 14(2):381–6. Epub 2011/03/16. doi: 10.1016/j.jval.2010.09.008 PMID: 21402305.

41. Barnett AG, Page K, Campbell M, Martin E, Rashleigh-Rolls R, Halton K, et al. The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections: a case-control study. BMJ Open. 2013; 3(10):e003587. Epub 2013/11/02. doi: 10.1136/bmjopen-2013-003587 PMID: 24176795; PubMed Central PMCID: PMCPMC3816236.

42. Australian Institute of Health and Welfare accessed 1st March 2014. Australian hospital statistics 2011–12. Health services series no. 50. Cat. no. HSE 134 (Table B.S11), available here (http://www.aihw.gov.au/publication-detail/?id=60129543133). Canberra: AIHW; 2013.

43. Rechner IJ, Lipman J. The costs of caring for patients in a tertiary referral Australian Intensive Care Unit. Anaesth Intensive Care 2005; 33(4):477–82. PMID:16119489

44. Australian Institute of Health & Welfare. Australia’s health 2010. Australia’s health series no. 12. Cat. no. AUS 122, available herehttps://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442452958. 2010. Canberra: AIHW.

45. Australian Institute of Health and Welfare (AIHW) accessed 1st March 2014. Life Expectancy, available at http://www.aihw.gov.au/deaths/life-expectancy/, 2012.

46. George B HA, Mitchell A,. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001; 19:1103–9. PMID:11735677

47. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics. 1999; 18:341–64. PMID:10537899

48. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005; 14:339–47. PMID: 15736142

49. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Economics. 2001; 10(8):779–87. PMID:11747057

50. Graves N, Halton K, Page K, Barnett A. Linking scientific evidence and decision making: a case study of hand hygiene interventions. Infect Control Hosp Epidemiol. 2013; 34(4):424–9. Epub 2013/03/08. doi: 10.1086/669862 PMID: 23466917.

51. Australian Institute of Health and Welfare. Australian hospital statistics 2012–13: Staphylococcus aureus bacteraemia in Australian public hospitals. Health services series no 53 Cat no HSE 144 [Internet]. 2013.

52. Page K, Barnett AG, Campbell M, Brain D, Martin E, Fulop N, et al. Costing the Australian National Hand Hygiene Initiative. Available here http://www.cre-rhai.org.au/manuscripts-in-press Journal of Hospital Infection. In Press.

53. Dick AW, Perencevich EN, Pogorzelska-Maziarz M, Zwanziger J, Larson EL, Stone PW. A decade of investment in infection prevention: a cost-effectiveness analysis. (1527–3296 (Electronic)).

54. Lawes T, Lopez-Lozano JM, Nebot CA, Macartney G, Subbarao-Sharma R, Dare CR, et al. Effects of national antibiotic stewardship and infection control strategies on hospital-associated and community-associated meticillin-resistant Staphylococcus aureus infections across a region of Scotland: a non-linear time-series study. Lancet Infect Dis. 2015; 15(12):1438–49. Epub 2015/09/29. doi: 10.1016/s1473-3099(15)00315-1 PMID: 26411518.

55. Lawes T, Lopez-Lozano JM, Nebot C, Macartney G, Subbarao-Sharma R, Dare CR, et al. Turning the tide or riding the waves? Impacts of antibiotic stewardship and infection control on MRSA strain dynamics in a Scottish region over 16 years: non-linear time series analysis. BMJ Open. 2015; 5(3):e006596. Epub 2015/03/31. doi: 10.1136/bmjopen-2014-006596 PMID: 25814495; PubMed Central PMCID: PMCPMC4386222.

56. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol. 2006; 6:54. Epub 2006/11/10. doi: 10.1186/1471-2288-6-54 PMID: 17092344; PubMed Central PMCID: PMC1636652.

57. Lawes TG, Gould IM. Dissecting a multi-intervention meticillin-resistant Staphylococcus aureus prevention bundle may miss emergent properties. Clin Infect Dis. 2012; 55(7):1027–8; author reply 8–9. Epub 2012/07/05. doi: 10.1093/cid/cis602 PMID: 22761407.

58. Stewardson AJ, Harbarth S, Graves N. Valuation of hospital bed-days released by infection control programs: a comparison of methods. Infect Control Hosp Epidemiol. 2014; 35(10):1294–7. Epub 2014/09/10. doi: 10.1086/678063 PMID: 25203185.
59. Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of health care-associated infections: mind your p's and q's. Clin Infect Dis. 2010; 50(7):1017–21. Epub 2010/02/25. doi: 10.1086/651110 PMID: 20178419.